Navigation Links
Interim Results Reported for Phase I Open-Label Clinical Trial for the Treatment of PTSD and MDD Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
Date:5/30/2012

LOS ANGELES, May 30, 2012 /PRNewswire/ -- Today, at the 52nd annual New Clinical Drug Evaluation Unit (NCDEU) Conference in Arizona, Ian Cook, M.D., Professor of Psychiatry at the University of California, Los Angeles (UCLA) and a Senior Medical Advisor to NeuroSigma, Inc., presented the results from the first 6-subject cohort of a 10-subject Phase I open-label clinical trial studying the effects of external trigeminal nerve stimulation (eTNS™) on Post-Traumatic Stress Disorder (PTSD) and depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy.  The trial is being conducted at UCLA and is funded by NeuroSigma.  Mean decreases in PTSD measures of 36% and depression measures of over 50% were reported.

The study was conducted over an 8-week period and followed similarly designed eTNS trials conducted at UCLA, in which promising results were generated in treating both major depression and epilepsy.  Subjects had a mean age of 54 with a median of 28 years since traumatic exposure and suffered from both PTSD and MDD.  Current episodes were required to be of at least four months in duration, with non-response to at least one antidepressant.  In this outpatient trial, subjects placed stimulating eTNS electrodes on their foreheads for approximately eight hours each night while asleep, and the severity of PTSD and depression symptoms was measured every two weeks using standard recognized rating scales. 

"These findings are very encouraging," said Dr. Cook.  "The combination of depression and an anxiety disorder, like PTSD, is usually difficult to treat effectively.  The participants in the study told us that eTNS was easy to use at home and led, in some instances, to the best mental health they had experienced in years.  We expect these results, along with results from the remaining subjects in this Phase I trial, to form the basis for an upcoming Phase II clinical trial
'/>"/>

SOURCE NeuroSigma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
2. Codexis Appoints Interim Chief Executive Officer
3. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
4. Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007 in Patients with Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
5. Breast Cancer Vaccine Reduces Cancer Recurrence in Women: Interim Results From Phase 2 Clinical Trial Trend Toward AE37 Vaccine Benefit; Results Presented at SABCS
6. Golden Meditech FY2011-12 Interim Results
7. Positive Interim Results from Interferon-Free Phase 2b SOUND-C2 Study with Boehringer Ingelheims Two Investigational HCV Direct Acting Antivirals Presented at AASLD
8. Interim Data Announced for BIBF 1120 as Compared to bevacizumab in Combination Chemotherapy in Metastatic Colorectal Cancer
9. Dr. Eva Feldman, Principal Investigator, Presents Interim Data on Neuralstem ALS Trial
10. Niiki Pharma Announces Positive Interim Data from Ongoing Clinical Trial of Novel Anti-Cancer Agent NKP-1339
11. Landauer Elects Board Member Michael T. Leatherman as Interim Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the ... Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... in order to treat dental impairments, for tooth restoration ...
(Date:1/15/2014)... 2014 Massachusetts General Hospital (MGH), the Broad ... announced today that they have launched a strategic ... targets and develop novel therapies for inflammatory bowel ... worldwide. The MGH-Broad-Amgen collaboration brings together scientists with ...
(Date:1/15/2014)... Fla. , Jan. 15, 2014  In an unprecedented effort to ... TB in ambulances and other transport vehicles, an advanced and portable ... rescue personnel for the first time. In order ... with these deadly pathogens, West Palm Beach ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2
... , April 26 e-MDs, an industry leader ... and practice management (PM) solutions, announced they have been selected ... Alaska EHR Alliance (AEHRA).   e-MDs was identified through ... Alaska healthcare providers looking to incorporate an EHR in ...
... 26 Sirion Therapeutics, Inc., a privately held ophthalmic ... is now commercially available.  Zirgan™, which was approved by the ... is a topical ophthalmic antiviral indicated for the treatment of ... , , ...
Cached Medicine Technology:Alaska EHR Alliance Selects e-MDs as Recommended Electronic Health Record Vendor 2Alaska EHR Alliance Selects e-MDs as Recommended Electronic Health Record Vendor 3Alaska EHR Alliance Selects e-MDs as Recommended Electronic Health Record Vendor 4Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 2Sirion Therapeutics Announces Availability of Zirgan(TM) (ganciclovir ophthalmic gel) 0.15% for Ocular Herpes 3
(Date:7/10/2014)... as tempting as full-fat equivalents could be heading ... how proteins can replace fats without affecting foodstuffs, ... Engineering and Physical Sciences Research Council (EPSRC), a ... Edinburgh has produced modified proteins that easily break ... behaviour of fats during food manufacture. The proteins ...
(Date:7/9/2014)... 2014 -- The World Health Organization recommends that youth ... to vigorous physical activity (MVPA) each day. Studies ... during school hours. Therefore, it stands to reason ... MVPA. In a new study scheduled for publication ... that time spent outdoors after school was positively associated ...
(Date:7/9/2014)... Perelman School of Medicine at the University of Pennsylvania ... received an $8 million grant from the National Cancer ... therapy (PDT) in patients with malignant pleural mesothelioma, a ... itself in the lining of the lungs and is ... will fund a clinical trial and additional studies looking ...
(Date:7/9/2014)... Studying the most common type of lung cancer, researchers ... a role in forming tumors. The new knowledge may ... these genetic changes already are available or are in ... , investigators from The Cancer Genome Atlas (TCGA), including ... Louis, Harvard Medical School and other institutions, studied tumors ...
(Date:7/9/2014)... used in policing injection drug users in Russia ... , A study, conducted by researchers from ... in collaboration with St. Petersburg Pavlov State University, ... on the health outcomes of a cohort of ... , Those who were arrested by police were ...
Breaking Medicine News(10 mins):Health News:Great tasting low-fat cheeses and cakes could soon be on the menu 2Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Lung cancer study hints at new treatments 2Health News:BU researchers relate arrests with HIV risk environment 2
... nutritional supplement used by weightlifters and sprinters to improve ... muscular dystrophies. ,Muscle strength increased by an ... to those who did not use the supplement, according ... gained an average of 1.4 pounds more lean body ...
... promise for people suffering from insomnia, particularly narcolepsy - a ... during waking hours.// ,The first phase of the ... 70 males for about 12 hours, who were healthy and ... ,They found that when orexin, a neuropeptide that ...
... can be used as an oral contraceptive for birth control ... and Drug Administration have formulated this drug especially for woman, ... dysphoric disorders. ,The YAZ drug, manufactured by Bayer ... by the FDA for three distinct uses. ,Phil ...
... life of common man. They are intended to boost the sale ... When it comes to promoting// drugs through commercials, the campaigns are ... don’t need them. ,This was revealed in a survey ... University of California – Los Angeles Department of Medicine. This group ...
... in at least ten districts of Nairobi. This was announced ... Munyao declared that 100,000 doses of vaccines are being distributed ... of insecticides have also been handed over to these places. ... due to RVF and four hundred cases are reported sick. ...
... ,The Canadian Football League linebacker and father of two, ... was infected with HIV while having sexual relationships with two ... with the court, Smith tested HIV positive and was informed ... asked to inform his sexual partners about this and to ...
Cached Medicine News:Health News:Creatine Supplement May Help People With Muscular Dystrophies 2
VG1 ALIF (Anterior Lateral) Anterior lumbar interbody fusion. Frozen freeze-dried preservation....
Allograft implants can be easily used to repair and promote the healing of a wide variety of bone and other tissue defects....
Allograft implants can be easily used to repair and promote the healing of a wide variety of bone and other tissue defects....
Duet Lumbar Allografts are comprised of a raised cancellous inner core providing biomechanical properties for rapid healing. Specially designed instruments facilitate the insertion of Duet Allografts...
Medicine Products: